科倫博泰生物－Ｂ
No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park Wenjiang District
Chengdu
China
https://kelun-biotech.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1,415
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Junyou Ge | President, CEO, COO, GM & Executive Director | 3.93M | 無 | 1972 |
| Dr. Jingyi Wang | Executive Director | 2.9M | 無 | 1960 |
| Mr. Zejian Zhou | CFO & Joint Company Secretary | 無 | 無 | 1983 |
| Mr. Yong Guo | Deputy GM, Chief Commercial Officer & Chief Marketing Officer | 無 | 無 | 1970 |
| Mr. Yi Feng | Deputy GM, Chief Strategy Officer & Senior VP | 無 | 無 | 1966 |
| Dr. Xiangyang Tan | Deputy GM and Chief Scientific Officer of Biologics' Research & Development | 無 | 無 | 1963 |
| Dr. Xiaoping Jin | Deputy GM & Chief Medical Officer | 無 | 無 | 1978 |
| Ms. Wai Sum Fung A.C.I.S., A.C.S. | Joint Company Secretary | 無 | 無 | 1983 |
描述
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
公司管治
截至 無 止，科倫博泰生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
